Abstract
The presymptomatic stages of frontotemporal dementia (FTD) are still poorly defined and encompass a long accrual of progressive biological (preclinical) and then clinical (prodromal) changes, antedating the onset of dementia. The heterogeneity of clinical presentations and the different neuropathological phenotypes have prevented a prior clear description of either preclinical or prodromal FTD. Recent advances in therapeutic approaches, at least in monogenic disease, demand a proper definition of these predementia stages. It has become clear that a consensus lexicon is needed to comprehensively describe the stages that anticipate dementia. The goal of the present work is to review existing literature on the preclinical and prodromal phases of FTD, providing recommendations to address the unmet questions, therefore laying out a strategy for operationalizing and better characterizing these presymptomatic disease stages.
| Original language | English |
|---|---|
| Pages (from-to) | 1408-1423 |
| Number of pages | 16 |
| Journal | Alzheimer's and Dementia |
| Volume | 18 |
| Issue number | 7 |
| DOIs | |
| Publication status | Published - 1 Jul 2022 |
Bibliographical note
ACKNOWLEDGMENTSThis project received support from the JPND grant “GENFI-prox” to M.S, J.D.R., and B.B. M.B. is supported by a Fellowship award from the Alzheimer's Society, UK (AS-JF-19a-004-517). M.B.’s work is also supported by the UK Dementia Research Institute, which receives its funding from DRI Ltd, funded by the UK Medical Research Council, Alzheimer's Society, and Alzheimer's Research UK. J.D.R. is supported by an MRC Clinician Scientist Fellowship (MR/M008525/1) and has received funding from the NIHR Rare Disease Translational Research Collaboration (BRC149/NS/MH).
Publisher Copyright:
© 2021 The Authors. Alzheimer's & Dementia published by Wiley Periodicals LLC on behalf of Alzheimer's Association.
